Paying for One-Off Therapies: Annuities, Outcomes-Based Deals and Practical Limits

A single treatment with lasting benefit creates a problem that conventional budgets are not built to solve: a large cost paid today for benefit that accrues over many years. Payment models have been proposed to spread cost and risk, but each has practical limits.

The payer’s problem

Gene and other advanced therapies are often given once. Payers face a high upfront cost, uncertainty about how long benefit lasts, and annual budgets that do not carry costs across years. That combination makes the headline price difficult to absorb even when long-term value is plausible.

The main payment designs

Several structures recur in the literature.

  • Annuity payments: the cost is spread over several years rather than paid at administration.
  • Outcomes-based payments: payment, or part of it, depends on the patient meeting agreed clinical criteria over time.
  • Rebates or refunds: money returns to the payer if the therapy does not deliver the defined result.
  • Financial agreements: discounts, caps or volume-linked arrangements that do not depend on individual outcomes.

Where the difficulties lie

Outcomes-based models need measurable endpoints, a reliable way to collect follow-up data, and agreement on what happens when a patient moves between providers or leaves the country. Administrative burden can outweigh the savings. Annuities depend on payers being willing to commit future budgets and on clarity about what happens if the patient dies or changes insurer. Analyses of specific products have shown that the financial effect for the payer depends heavily on the design chosen, so modelling alternatives before negotiation is worthwhile.

Fitting the model to the system

In Greece, managed entry agreements, rebates and the national clawback framework are already part of the landscape, so any proposal must fit those rules. A simple, auditable arrangement is generally easier to operate than a complex one. Define data sources, responsibilities and timelines in the agreement itself, and confirm that the health system can actually collect the information required.

Preparing before the negotiation

The best preparation is to understand the payer’s constraints. How are budgets set and carried over? Who holds the data that an outcomes-based arrangement would need? What legal basis exists for payments over time or for refunds? These questions often matter more than the choice of model itself.

It also pays to prepare the clinical evidence to match the agreement. If payment depends on durability, the company should be able to explain what is known about duration of effect, what remains unknown, and what long-term follow-up is planned. Candour on uncertainty builds the trust that complex agreements require, and a model that the payer understands and can operate is more valuable than a sophisticated one that cannot be administered.

How PQRA helps

PQRA can support the market access strategy for advanced therapies, including how different payment concepts might be received by European payers and how they sit within national rules.

If you are planning access for a one-off therapy, Contact PQRA.

CATEGORIES:

Uncategorized

Tags:

No responses yet

Leave a Reply

Your email address will not be published. Required fields are marked *